Get the Stockscreener App
6.40
0.16%
-0.010
After Hours:
6.30
-0.10
-1.56%
Upstream Bio Inc stock is traded at $6.40, with a volume of 459.47K.
It is down -0.16% in the last 24 hours and down -5.19% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$6.41
Open:
$6.47
24h Volume:
459.47K
Relative Volume:
0.81
Market Cap:
$348.29M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-2.2055
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
-8.31%
1M Performance:
-5.19%
6M Performance:
-80.31%
1Y Performance:
-53.04%
1-Day Range:
$6.26
$6.60
1-Week Range:
$6.16
$7.08
52-Week Range:
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.40 | 348.83M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
UPB|Upstream Bio Inc|Price:6.410|Chg%:+0.010 - TradingKey
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Upstream Bio, Inc. Revenue Breakdown – NASDAQ:UPB - TradingView
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Why Did UPB Stock Plunge 40% Today? - Stocktwits
ETFs Investing in Upstream Bio, Inc. Stocks - TradingView
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
UPB Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Season Preview - DonanımHaber
Upstream Bio Q1 2026 Earnings: Narrower Loss Beats Expectations, Stock Declines in Pre-Revenue Phase - dars.gov.et
Price to earnings forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPBUpstream Bio Inc Dividends - Finviz
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Miss Alert - DonanımHaber
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock DeclineDiluted EPS Report - dars.gov.et
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UpStream Bio(UPB) Stock Options Chain | Quotes & News - Moomoo
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGross Profit Margin - dars.gov.et
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB) - TradingView
Upstream Bio, Inc. Actuals & Estimates (BOATS:UPB) - TradingView
UPB Forecast — Price Target — Prediction for 2027 - TradingView
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Insider Monkey
Enterprise value to EBITDA forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
JPMorgan Cuts Upstream Bio Stock Target to Eight Dollars - sekbernews.id
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026? - Yahoo Finance
Upstream Bio (UPB) Consolidates Near Support After Marginal Gains Amid Biotech Sector CautionIV Rank - dars.gov.et
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
UPB Technical Analysis & Stock Price Forecast - Intellectia AI
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Upstream Bio Inc (UPB) Institutional Confidence - TradingKey
Top Executive Makes Strategic Move With Upstream Bio Stock - TipRanks
Upstream Bio Inc (UPB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Upstream Bio Presents New Responder Analyses Demonstrating - GlobeNewswire
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEstimate Accuracy - newsline.com
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):